ABCL AbCellera Biologics
AI-driven antibody discovery
Fundamentals from public market data, refreshed daily (2026-10-24 02:59 UTC). Figures in reporting currency.
ABCL · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-08-05EarningsMiss / cut
Reported EPS -0.18 vs -0.16 expected (-9.1% surprise).
-
7
2026-05-11EarningsBeat / raise
Reported EPS -0.14 vs -0.2 expected (+29.1% surprise).
-
6
2026-02-24EarningsBeat / raise
Reported EPS -0.03 vs -0.18 expected (+83.3% surprise).
-
5
2025-11-06EarningsMiss / cut
Reported EPS -0.19 vs -0.16 expected (-17.3% surprise).
-
4
2025-08-07EarningsBeat / raise
Reported EPS -0.12 vs -0.16 expected (+26.5% surprise).
-
3
2025-05-08EarningsMiss / cut
Reported EPS -0.15 vs -0.14 expected (-5.3% surprise).
-
2
2025-02-27EarningsBeat / raise
Reported EPS -0.12 vs -0.15 expected (+20.8% surprise).
-
1
2024-11-04EarningsMiss / cut
Reported EPS -0.17 vs -0.13 expected (-30.8% surprise).
Latest headlines
Auto-updated daily- AbCellera to Present at Upcoming Investor Conferences in November 20262026-10-22
- AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus2026-10-09
- AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting2026-10-08
- AbCellera to Report Third Quarter 2026 Financial Results on November 9, 20262026-10-01
- AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 20262026-09-16
- Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?2026-08-14
- AbCellera (ABCL) Q2 2026 Earnings Call Transcript2026-08-13
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.16 | -0.18 | −9.1% |
| 2026-05-11 | -0.2 | -0.14 | +29.1% |
| 2026-02-24 | -0.18 | -0.03 | +83.3% |
| 2025-11-06 | -0.16 | -0.19 | −17.3% |
| 2025-08-07 | -0.16 | -0.12 | +26.5% |
| 2025-05-08 | -0.14 | -0.15 | −5.3% |
| 2025-02-27 | -0.15 | -0.12 | +20.8% |
| 2024-11-04 | -0.13 | -0.17 | −30.8% |
| 2024-08-06 | -0.14 | -0.13 | +9.3% |
| 2024-05-07 | -0.16 | -0.14 | +13.3% |
| 2024-02-20 | -0.12 | -0.16 | −33.3% |
| 2023-11-02 | -0.13 | -0.1 | +22.2% |
| 2023-08-03 | -0.12 | -0.11 | +10.8% |
| 2023-05-04 | -0.13 | -0.14 | −6.1% |
| 2023-02-21 | -0.01 | -0.1 | −900.0% |
| 2022-11-08 | 0.05 | 0.08 | +77.8% |
| 2022-08-09 | — | -0.02 | −400.0% |
| 2022-05-10 | 0.42 | 0.54 | +29.3% |
| 2022-02-24 | 0.18 | 0.19 | +8.6% |
| 2021-11-09 | -0.06 | -0.08 | −41.2% |
| 2021-08-12 | 0.09 | -0.01 | −110.7% |
| 2021-05-13 | 0.38 | 0.37 | −3.5% |
| 2021-03-29 | 0.81 | 0.37 | −54.3% |
About AbCellera Biologics
Website ↗AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune dis…
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | AI drug discovery with NVIDIA-backed compute | $3.77 | +1.89% | +0.8% | −7.8% | |
| SDGR Schrödinger | Physics-plus-AI molecular design software | $24.60 | +3.36% | −14.7% | +37.6% | |
| ABSI Absci | Generative-AI antibody design | $9.55 | +4.03% | −1.9% | +173.6% | |
| TEM Tempus AI | Clinical and genomic data for AI diagnostics | $66.46 | −1.71% | −21.8% | +12.6% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.